News

BOSTON, Mass., Nov. 9, 2026 — Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced additional data from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel once-daily dual calcium channel antagonist, for the treatment of systemic sclerosis-associated Raynaud’s phenomenon (SSc RP). The data will be presented in

BOSTON, March 6, 2026 /PRNewswire/ — Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel once-daily calcium channel blocker, for the treatment of systemic sclerosis-associated Raynaud’s phenomenon (SSc RP). The results were presented in an oral presentation at the

Company also provides updates on its Phase 2 RECONNOITER Study in Raynaud’s Phenomenon and Systemic Sclerosis and other corporate activities BOSTON, Sept. 9, 2024 /PRNewswire/ — Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AISA-021(cilnidipine), a fourth-generation calcium channel antagonist.

Phase 2 Data at EULAR AISA-021 Treatment Might Influence Systemic Sclerosis (SSc) Disease Severity BOSTON, June 21, 2023 /PRNewswire/ — Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company today announced initiation of Part 2 of the RECONNOITER Phase 2 study, evaluating AISA-021, a once-daily novel, oral calcium-channel antagonist (CCB) in patients with SSc and Raynaud’s phenomenon(SSc-RP). The study is

April 3, 2023 – Boston, MA : Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company, announces that the National Institute of Neurological Disorders and Stroke (NINDS)- National Institutes of Health (NIH) have awarded the Preclinical Screening Pain Platform (PSPP) award to Aisa’s AISA-021 (cilnidipine), a once-daily novel, investigational, oral calcium-channel antagonist. The PSPP was created

AISA-021 impact on key Nav 1.7 pain channel to be presented at AANInitial Positive Phase 2 data from RECONNOITER-1 Trial in Systemic Sclerosis patients with Raynaud’s Phenomenon to be presented at EULAR April 3, 2023 – Boston, MA : Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company, today announced it will present data on its

Company to Move Forward with Key U.S. Regulatory Applications – Investigational New Drug and Orphan Drug Designation BOSTON, July 26, 2022 — Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, today announced that the Data Safety Monitoring Board (DSMB) for the RECONNOITER Phase 2 study of Aisa’s AISA-021 once-daily novel, oral calcium-channel antagonist has met

AISA Pharma Announces Initiation of Patient Enrollment in Phase 2 Trial of Novel Therapy for Raynaud’s Disease in Scleroderma June 16, 2021 – Boston, MA : Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, announces that it has begun enrolling patients in a Phase 2 study evaluating the novel investigational therapy AISA-021 in patients with